Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.50 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.50 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.50 |
| ▸ | MAOA | P21397 | 2/20 | 0.50 |
| ▸ | TSHR | P16473 | 2/20 | 0.44 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.44 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.44 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.44 |
| ▸ | PHLPP2 | Q6ZVD8 | 1/20 | 0.43 |
| ▸ | PARP10 | Q53GL7 | 1/20 | 0.42 |
| ▸ | NPC1 | O15118 | 3/20 | 0.42 |
| ▸ | MAPT | P10636 | 3/20 | 0.42 |
| ▸ | RAB9A | P51151 | 3/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | GSK3B | P49841 | 1/20 | 0.41 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.41 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.41 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.41 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.41 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7290567 | 0.81 | CA1 (0.54) | TSHRNPC1MAPTRAB9AALDH1A1 | |
| SCHEMBL863102 | 0.81 | ESR2 (0.59) | NPC1MAPTRAB9AALDH1A1ESR2 | |
| SCHEMBL2064455 | 0.81 | NPC1 (0.58) | LMNATSHRNPC1MAPTRAB9A | |
| SCHEMBL12241879 | 0.79 | PARP10 (0.49) | CYP3A4MAOATSHRPARP10NPC1 | |
| SCHEMBL12241900 | 0.79 | MEN1 (0.54) | LMNACYP1A2CYP3A4CYP2C9CYP2C19 | |
| SCHEMBL7290231 | 0.79 | GSK3B (0.41) | LMNANPC1MAPTRAB9AALDH1A1 | |
| SCHEMBL6040897 | 0.79 | TPMT (0.46) | NPC1MAPTRAB9AGSK3BHDAC3 | |
| SCHEMBL20135229 | 0.79 | MAPT (0.62) | LMNATSHRNPC1MAPTRAB9A | |
| SCHEMBL11430934 | 0.79 | GSK3B (0.57) | LMNANPC1MAPTRAB9AALDH1A1 | |
| SCHEMBL10796669 | 0.79 | HAO1 (0.46) | LMNATSHRNPC1MAPTRAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114940695-A | Androsterone derivative with anti-tumor activity and preparation method and application thereof | 济南爱思医药科技有限公司 | 2022-08-26 | — | — | CN | disclosed |
| EP-3205645-B1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICALS CO (JP) | 2019-10-23 | — | — | EP | disclosed |
| US-9957251-B2 | Heterocyclic compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2018-05-01 | — | — | US | disclosed |
| EP-3205645-A1 | HETEROCYCLIC COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2017-08-16 | — | — | EP | disclosed |
| EP-2534132-B1 | SUBSTITUTED PYRROLIDINE-2-CARBOXAMIDES | HOFFMANN LA ROCHE (CH) | 2017-04-26 | — | — | EP | disclosed |
| US-20170044132-A1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2017-02-16 | — | — | US | disclosed |
| US-8952190-B2 | Synergists | SUN CHEMICAL B.V. (NL) | 2015-02-10 | — | — | US | disclosed |
| US-8952190-B2 | Synergists | SUN CHEMICAL B.V. (NL) | 2015-02-10 | — | — | US | disclosed |
| EP-2014643-B1 | PARA-METHOXYANILINE DERIVATIVES INCREASING THE ANTIKNOCK RATING OF HYDROCARBON FUELS AND COMPOSITIONS BASED THEREON | ZAO IFOKHIM (RU) | 2013-11-20 | — | — | EP | disclosed |
| US-20130012611-A1 | SYNERGISTS | SUN CHEMICAL B.V. (NL) | 2013-01-10 | — | — | US | disclosed |
| US-20130012611-A1 | SYNERGISTS | SUN CHEMICAL B.V. (NL) | 2013-01-10 | — | — | US | disclosed |
| EP-2014643-A1 | PARA-ETHOXYANILINE DERIVATIVES INCREASING THE ANTIKNOCK RATING OF HYDROCARBON FUELS AND COMPOSITIONS BASED THEREON | Obshestvo S Ogranichennoy Otvetstvennostiu Inoxim (RU) | 2009-01-14 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130012611-A1 | SYNERGISTS | RAD51, MRE11, RAD52 | LMNA 427/4885CYP1A2 137/4885CYP3A4 435/4885 |
| US-20170044132-A1 | HETEROCYCLIC COMPOUND | CDK19, CDK9, CDK8 | LMNA 2027/4885CYP1A2 3250/4885CYP3A4 3104/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.